Ensuring patient access to our medicines
Payers are responsible for either making decisions or influencing the decisions of their organisation or country to reimburse, list and pay for drugs. To make sure that we meet the needs of this important customer, this Capability focuses on continuously incorporating payer perspectives from early on and at every stage of the product lifecycle to achieve and maintain patient access to our medicines.
NKTR-118 is an oral peripherally-acting opioid antagonist, under investigation for the treatment of opioid-induced constipation. For NKTR-118, we gathered input from a key customer group, the payer before commencing the Phase III program. We used the insight from the Payer as well as regulatory authority feedback to shape our clinical development approach and Phase III KODIAC pivotal study design.